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OBJECTIVES This study was designed to fully characterize vascular tissue angiotensin I (AI)/angiotensin II
(AII) conversion changes over time in vivo in humans during chronic angiotensin-converting
enzyme (ACE) inhibitor therapy.
BACKGROUND Plasma AII does not remain fully suppressed during chronic ACE inhibitor therapy.
However, the plasma renin angiotensin system (RAS) might be dissociated from the vascular
tissue RAS. We therefore set out to characterize the time course of vascular RAS reactivation
during chronic ACE inhibitor therapy.
METHODS Vascular AI/AII conversion was studied in patients with chronic heart failure (CHF) taking
chronic lisinopril therapy by the differential infusion of AI and AII into the brachial artery. A
cross-sectional study was done to see whether there were differences in vascular AI/AII conversion
according to New York Heart Association (NYHA) class. A second longitudinal study followed
28 patients with NYHA I to II CHF serially over 18 months to see whether vascular ACE
inhibition was progressively lost with time despite ACE inhibitor therapy. A third study examined
whether increasing the dose of lisinopril affected subsequent vascular ACE inhibition.
RESULTS In the cross-sectional study, vascular AI-to-AII conversion was significantly reduced in
NYHA class III compared with class I/II (p 0.05). In the longitudinal study, vascular ACE
inhibition was significantly reduced at 18 months as compared with baseline (p  0.001),
suggesting gradual reactivation of vascular ACE in CHF over time. In the third study, tissue
ACE inhibition could be restored by increasing the ACE inhibitor dose.
CONCLUSIONS Vascular AI/AII conversion reactivates over time during chronic ACE inhibitor therapy even
if the CHF disease process is clinically stable. It also occurs as the CHF disease process
progresses. Even if vascular AI/AII conversion has reactivated, it can be suppressed by
increasing the dose of the ACE inhibitor. (J Am Coll Cardiol 2002;39:767–75) © 2002 by
the American College of Cardiology Foundation
Angiotensin-converting enzyme (ACE) inhibitors have
clearly been a major advance in the treatment of chronic heart
failure (CHF), but cross-sectional studies have suggested that
plasma angiotensin II (AII) does not remain suppressed in all
patients with CHF during chronic ACE inhibitor therapy
(1,2). However, plasma levels of AII are not that informative
because it is now well accepted that there are two very different
components to the renin angiotensin system (RAS); there is
the circulating RAS and the tissue RAS (3–5), and several
indirect lines of evidence suggest that the circulating RAS and
the tissue RAS are often dissociated (5–7).
See page 776
The question naturally arises whether vascular tissue
ACE reactivates over time during chronic ACE inhibitor
therapy. Preliminary evidence, again only from cross-
sectional studies, shows that human tissues can sometimes
generate AII from angiotensin I (AI) during chronic ACE
inhibitor therapy (8,9). However, cross-sectional studies
where different individuals are studied only once are clearly
an imperfect, if not a flawed, way to study a phenomenon
thought to occur gradually within an individual over time.
The definitive way to study such a phenomenon is to do a
longitudinal study in which the same individuals are studied
repeatedly. But there are as yet no longitudinal studies to
examine whether vascular tissue AI/AII conversion reacti-
vates progressively over time within an individual during
chronic ACE inhibitor therapy. There are also no data to
see whether vascular AI/AII conversion is reactivated even
more when CHF disease progresses as it usually does. We
sought to answer both these questions, and also considered
whether increasing the ACE inhibitor dose would help
when vascular AI/AII conversion has reactivated. After all,
it is possible that during chronic ACE inhibitor therapy,
non-ACE pathways could contribute to vascular tissue AII
generation, such that increasing the ACE inhibitor dose
further at the late stages of the disease would have little
impact on vascular tissue AII generation. A fourth question
that we addressed was whether reactivation of vascular tissue
AII generation was dissociated from reactivation of the
plasma RAS.
METHODS
Study populations (Table 1). All studies received local
ethical approval and all subjects gave written informed consent.
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STUDY 1: CROSS-SECTIONAL STUDY. In the first study, 37
patients (age 64  7 years) with New York Heart Associ-
ation (NYHA) class I to III CHF were studied in a
cross-sectional fashion using a standard vascular function
protocol to see whether any differences in vascular ACE
activity could be observed according to disease severity by
NYHA class. The three groups (NYHA I, II and III) were
matched by age, gender and ACE inhibitor dose. All
patients were taking the ACE inhibitor lisinopril to avoid
any confounding issues with regard to differences in tissue
ACE binding properties with different ACE inhibitors.
Unfortunately, NYHA class IV patients cannot be studied
with this technique because they cannot lie flat for several
hours.
STUDY 2: LONGITUDINAL STUDY. Twenty-eight patients
with NYHA class I and II CHF taking a fixed dose of
lisinopril were studied at baseline, after nine months and
after 18 months to see whether there was any progressive
loss of vascular ACE inhibition over time despite chronic
ACE inhibitor therapy.
STUDY 3: CHANGING ACE INHIBITOR DOSE STUDY. Ten
patients with the least vascular ACE inhibition seen in
Study 1 were restudied on three further occasions, taking a
baseline dose of lisinopril of 10 mg/day. Subjects had their
vascular function assessed at baseline, after taking lisinopril
5 mg/day for six weeks and after taking 20 mg/day for six
weeks. This was a double-blind crossover study with ran-
domization of treatment allocations. The study was de-
signed to see whether vascular AI/AII conversion could be
suppressed by increasing the dose of the ACE inhibitor.
Vascular function protocol. We assessed vascular AI/AII
conversion by forearm venous occlusion plethysmography
using a protocol described in detail by our group (10,11). All
study visits were carried out in the afternoon (2 PM), 6 h
after dosing with lisinopril to ensure peak drug effect.
Drug infusions. First, AI was infused at 16, 64, 256, 512
and 1,024 pmol/min, each for 7 min, to produce a cumu-
lative dose-response curve. This was followed by AII in-
fused at 4, 16, 64, 256 and 1,024 pmol/min for 7 min each.
Between the AI infusion and the AII infusion, the infusion
set was flushed with saline, and sufficient time was allowed
for the forearm blood flow to return to baseline values
(approximately 20 to 30 min).
Angiotensin I only exerts its vasoconstrictive effect in this
forearm model through conversion in the vasculature to AII,
and therefore the vasoconstriction elicited by AI reflects
vascular AI/AII conversion (12,13). This technique has
been validated and is now used extensively by us and many
other investigators (12,13).
Plasma analytes. For all studies, markers of plasma RAS
activity (AI and II, aldosterone, plasma ACE) were ana-
lyzed. Blood sampling was carried out using intravenous
cannulae (20 G) placed into dorsal hand veins to cause a
minimum of discomfort and disturbance to resting subjects.
Once blood samples were obtained, aliquots were centri-
fuged at 4°C, separated and stored at 70°C (AI and II) or
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AI  angiotensin I
AII  angiotensin II
ATLAS  Assessment of Treatment with Lisinopril
and Survival
CHF  chronic heart failure
FBF  forearm blood flow
NYHA  New York Heart Association
RAS  renin angiotensin system
Table 1. Baseline Demographic, Hemodynamic, Humoral and Treatment Characteristics of
Patient Subjects
Cross-Sectional
Study
Longitudinal
Study
Dose-Ranging
Study
Age (yrs) 64 (7) 62 (8) 63 (6)
Gender: M/F 31/6 22/6 9/1
NYHA class: class I/II/III 11/14/12 14/14 4/2/4
Smoking history: previous/never smokers 24/13 20/8 7/3
Mean BP, mm Hg 128 (6)/68 (4) 124 (6)/71 (3) 120 (2)/70 (4)
Left ventricular ejection fraction, % 30 (6) 28 (7) 28 (4)
Serum urea, mmol/l 7.3 (1.6) 6.8 (1.8) 7.0 (4.2)
Serum creatinine, mol/l 116 (24) 110 (20) 120 (18)
Serum total cholesterol, mmol/l 5.2 (0.2) 5.3 (0.3) 5.3 (0.4)
Mean dose of ACE inhibitor, mg/day
NYHA class I/II/III 15 (5)/17 (5)/15 (7) 16 (5)/17 (5) 15 (4)/15 (7)
Mean duration of ACE inhibition, years 5.2 (2.7) 3.6 (2.9) 4.1 (2.1)
Plasma glucose (random), mmol/l 5.6 (0.6) 5.4 (0.4) 5.5 (0.5)
Mean daily furosemide dose, mg/day 60 (15) 40 (20) 80 (20)
Concomitant medication
Nitrates 20 13 9
Digoxin 15 8 4
Calcium channel blocking drugs 12 6 5
Beta-blockers 24 18 6
ACE  angiotensin-converting enzyme; BP  blood pressure; NYHA  New York Heart Association.
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20°C (aldosterone, ACE) until assayed simultaneously in
a single batch.
Plasma AI and AII. Blood samples were taken into chilled
tubes containing ethylene diamine tetraacetic acid, enalkiren (a
renin inhibitor), enalapril (an in vitro ACE inhibitor) and
O-phenanthroline. In the presence of an ACE inhibitor
drug, chronic ACE inhibition prevents ACE-mediated
generation of AII, and feedback suppression of active renin
secretion is removed. In this setting, AII levels fall to the
attomolar range (1018 moles), with AI and related metab-
olites being increased on the order of 100-fold, creating
subsequent potential for cross-reactivity in radioimmuno-
assay for AII. Therefore, the different angiotensin peptides
are separated before specific AI or II radioimmunoassay us-
ing cross-reacting antibodies labeled with 125I, with subse-
quent high-performance liquid chromatography using a
octadecesilyl-silica stationary phase and changing (gradient)
and constant (isocratic) mobile phases. The intraassay and
interassay coefficients of variability were 10% for both
assays.
Plasma ACE and aldosterone assays. Blood aliquots were
taken into lithium heparin tubes, separated immediately and
stored at 20°C until analysis. Plasma ACE was deter-
mined by the standard spectophotometric kinetic rate
method, using the synthetic substrate N-3-(2-furyl)
acryloyl-L-phenylalanylglycyl-glycine. Aldosterone assays
were performed by an in-house radioimmunoassay using a
standard commercial kit (Sorin Biomedica, Saluggia, Italy).
The intraassay and interassay coefficients of variability were
9% for both assays.
Statistical analysis. Forearm blood flow (FBF) values were
expressed as ml/min per 100 ml forearm volume. These
blood flows were then converted to the ratio between the
increase in blood flow in the infused arm and the blood flow
in the control arm, according to the Whitney method (14).
Clinical characteristics between study visits were com-
pared using Student’s paired t tests. Statistical analysis of
FBF measurements for individual subjects were compared
between study visits using two-way analysis of variance with
repeated measures. The Bonferroni method for calculating
95% confidence intervals was the relevant multiple compar-
ison range test used, and the interaction term for within-
group effects in the dose-ranging study was the visit order,
to look for observable carryover effect independent from the
dose of treatment effect. A p value of 0.05 was considered
significant and a value of 0.01 highly significant. The
plethysmographic data were expressed as mean  standard
error of mean. In the dose-ranging study, there was no
statistically significant independent relationship between
visit order and FBF measurements (p 0.79), in contrast to
the marked influence of ACE inhibitor dose on FBF.
This statistical methodology has been validated as being
most accurate in reflecting true differences in blood flow
characteristics (10). The plethysmography technique itself is
well suited to relatively small studies in adults, being able to
detect a change of 20% with 90% power and p  0.05
in studies of 20 individuals studied on separate occasions
(15).
To see if there was any dissociation between plasma RAS
activation within an individual and vascular tissue RAS
activation in the same individual, we measured correlation
coefficients between relevant parameters.
RESULTS
Table 1 shows the basic demography of the patients in each
of the three studies.
Vascular Studies
Forearm vascular blood flow responses to AIand AII in
study I (cross-sectional study) (Fig. ). A significant in-
crease in AI-mediated vasoconstriction consistent with in-
creased vascular AI/AII conversion and reduced vascular
ACE inhibition was noted in those subjects with NYHA
class III CHF as compared to those with NYHA class I or
II CHF (maximum vasoconstriction 53  6% [NYHA
Figure 1. Forearm blood flow (FBF) responses to angiotensin I and II with
regard to New York Heart Association class: I (triangle), II (square) and
III (circle). *p  0.05.
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III] versus 44  5% [NYHA II] or 42  5% [NYHA
I]; p  0.05 for NYHA class III vs. class I, difference
between whole dose-response curves). In contrast, there
were no differences observed for the control vasoconstrictor
AII responses.
Forearm vascular blood flow responses to AI and AII in
study II (longitudinal study) (Fig. 2). There was a con-
sistent trend toward progressive activation of vascular AI/
AII conversion with time with regards to AI-mediated
vasoconstriction, with a significant increase in vasoconstric-
tion observed between baseline and 18-month visits (max-
imum vasoconstriction elicited was42 3% [baseline] vs.
63  2% [18-month visit], p  0.001 for difference
between dose-response curves). However, there was no
significant difference among the three study visits regarding
the forearm responses to the control vasoconstrictor AII
(Fig. 2), nor were there any changes over time in their
NYHA class or their doses of furosemide or lisinopril.
Forearm vascular responses to AI and AII with changes
in ACE inhibitor dosing (Fig. 3). There was significant
reduction in AI-mediated vasoconstriction on increasing the
ACE inhibitor lisinopril dose from 10 mg/day to
20 mg/day, implying substantial reinhibition of vascular
ACE (maximum vasoconstriction 64  3% [10mg/day]
versus 32  5% [20 mg/day], p  0.001 for difference for
dose-response curves). There was no significant reduction in
vascular ACE inhibition on halving the lisinopril dose to
5 mg/day (maximum vasoconstriction 69  2%). There
were no significant differences among the three study visits
regarding the forearm responses to the control vasoconstric-
tor AII.
Plasma Analytes
Differences in angiotensin peptides, aldosterone and
ACE levels according to NYHA class (Figs. 4 – 6). There
were no significant differences in AI, aldosterone or plasma
Figure 2. Forearm blood flow (FBF) responses to angiotensin I and
angiotensin II at baseline (square), after nine months (triangle) and after
18 months (circle). **p  0.001.
Figure 3. Forearm blood flow (FBF) responses to angiotensin I and
angiotensin II with differing dosages of angiotensin-converting enzyme
inhibitors: lisinopril 10 mg/day (square), lisinopril 5 mg/day (triangle) and
lisinopril 20 mg/day (circle). **p  0.001.
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ACE levels between patients with different NYHA classes
in the cross-sectional study (Fig. 4). However, there was a
significant rise in AII levels observed between NYHA
classes I/II and class III (6.1 2.1 pg/ml [NYHA I], 6.3
1.4 pg/ml [NYHA II] vs. 13.7  2.0 pg/ml [NYHA III];
p 0.005 for difference between NYHA classes II and III).
Figure 4. Differences in plasma angiotensin II, angiotensin II/I ratios,
angiotensin-converting enzyme (ACE) and aldosterone levels according to
New York Heart Association class. *p  0.05.
Figure 5. Changes in plasma levels of angiotensins, aldosterone and
angiotensin-converting enzyme (ACE) levels longitudinally with time.
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Accordingly the AII/I ratio was also significantly elevated
between NYHA classes I/II and III (0.04  0.009 [NYHA
II] vs. 0.07  0.01 [NYHA III]; p  0.03).
Changes in angiotensins, aldosterone and ACE levels
longitudinally with time. There was a significant increase
seen in AI levels between baseline and the two subsequent
study visits, although the most dramatic rise was observed in
the first nine months (169  29 pg/ml [baseline], 255 
37 pg/ml [nine months], 278  37 pg/ml; p  0.02
between baseline and nine months, p  0.006 between
baseline and 18 months). There were, however, no signifi-
cant changes in AII levels between study visits, nor were
there any changes seen in AII/I ratios, aldosterone or
plasma ACE levels (Fig. 5).
Angiotensin, aldosterone and ACE with changing dose
of ACE inhibitor. There were no significant changes
observed in any of the plasma parameters with either
increasing or decreasing the dose of lisinopril for 6 weeks
in the third study (Fig. 6).
Pressor dose responses to AI. The vascular tissue re-
sponses were also analyzed in a different way. In each of the
three studies, each individual dose-response curve to AI was
constructed to calculate for that individual the dose of AI
required to reduce forearm blood flow by 30% (the AI-
FBF30% value), which would indicate a clinically signifi-
cant change in blood flow related to vascular AI/AII
conversion by ACE in vivo. These individual values were
then averaged to look for differences among the three study
groups (Fig. 7).
In the cross-sectional study, there was a significant
reduction in AI-FBF30% between NYHA I and III groups
(p 0.005), indicative of increased vascular ACE activity in
the more severe disease class. We found a similar reduction
seen between NYHA II and III (p 0.013), although there
was no significant difference between the milder NYHA I
and II patient responses. In the longitudinal study, there
was a significant reduction in AI-FBF30% between base-
line and 18 months (p  0.01), implying increased vascular
AI/AII conversion with progression of time and a nearly
significant trend toward a similar increase in AI/AII con-
version between baseline and nine months (p  0.06). In
the dose-ranging study, there was a dramatic attenuation in
vascular AI/AII conversion between 5 mg and 20 mg/day
(p 0.0001), as well as between 10 mg and 20 mg/day (p
0.0001), although not between 5 mg and 10 mg/day. The
results thereafter are virtually identical whichever way the
vascular tissue AI/AII conversion results are calculated
(comparing Fig. 7 with Figs. 1–3).
Correlation coefficients comparing vascular flow indices
with plasma indices. There was no evidence of statistically
significant correlation between the absolute plasma and
vascular indices of RAS activity in any of the three studies
performed (Table 2).
In the longitudinal study, correlations between the
changes in AI-FBF30% values from baseline to 18 months
against changes in plasma AII and aldosterone over the
same time frame were calculated, but neither relationship
was statistically significant (Pearson’s correlation coeffi-
cients: R2 0.01 for aldosterone vs. AI-FBF30%, R
2 0.16
Figure 6. Plasma angiotensins, aldosterone and angiotensin-converting
enzyme with changing doses of angiotensin-converting enzyme (ACE)
inhibitor.
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for AII vs. AI-FBF30%). In the dose-ranging study, similar
correlation calculations were also not significant (R2  0.13
for aldosterone vs. AI-FBF30%, R
2  0.08 for AII vs.
AI-FBF30%). This is strong evidence of dissociation be-
tween plasma RAS activation and vascular tissue RAS
activation.
DISCUSSION
Our main study findings fall into four categories. First, even
in the presence of commonly used doses of ACE inhibitor
therapy, vascular AI/AII conversion was greater in the
severer cases of CHF. Second, even when the CHF disease
process appears stable clinically, as in our longitudinal study,
vascular AI/AII conversion increases gradually over time
despite chronic ACE inhibitor therapy. These latter data are
the most novel and the most important finding to arise from
these studies. Third, increasing the dose of the ACE
inhibitor markedly suppresses the reactivated vascular AI/
AII conversion seen during chronic ACE inhibitor therapy.
Fourth, interestingly, there was no correlation noted be-
tween any of the recognized markers of plasma RAS activity
and the derived vascular ACE activity responses, which
demonstrates for the first time in humans that there is
dissociation between the plasma and tissue ACE systems in
vivo. A larger sample size might have found statistical
significance, but given the very low r2 values we found, this
seems unlikely.
We did consider measuring ACE genotypes to see if this
determined AI/AII conversion, but there were two reasons
against it. First, there were no obvious interindividual
differences in vascular AI/AII conversion reactivation in our
study, and second, a genotype study with three genotypes in
only 28 individuals would be absurdly small and could lead
to erroneous conclusions. This is an issue that needs to be
studied more definitely in the future rather than be ad-
dressed by this study, which was really too small.
Experimental evidence suggests that blocking tissue ACE
activity requires higher than normal doses of ACE inhibi-
tors (16–18). In accordance with that finding, we found that
plasma ACE did not reflect the reactivation we saw in
vascular tissue AI/AII conversion. This was despite AI
Figure 7. Comparison of angiotensin I-FBF30% (forearm blood flow) in
each subgroup defined in the three studies in patients with chronic heart
failure.
Table 2. Correlation Coefficients (Pearson’s R2 Values)
Comparing Selected Vascular Blood Flow Parameters With
Indices of Plasma RAS Activation
AI-FBF30%
Maximal
FBF
Ang II 0.001 0.004
Ang I 0.017 0.039
Study 1 Ang II/I ratio 0.032 0.0001
ACE 0.001 0.008
Aldosterone 0.001 0.002
Ang II 0.001 0.001
Ang I 0.03 0.004
Study 2 Ang II/I ratio 0.007 0.0001
ACE 0.01 0.003
Aldosterone 0.0003 0.023
Ang II 0.001 0.028
Ang I 0.001 0.102
Study 3 Ang II/I ratio 0.011 0.105
ACE 0.009 0.1
Aldosterone 0.0007 0.163
None of the R2 values reached statistical significance of p  0.05.
ACE  angiotensin-converting enzyme; AI  angiotensin I; Ang  angiotensin;
FBF  forearm blood flow; RAS  renin angiotensin system.
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levels increasing between baseline and subsequent visits,
which was presumably due to accumulation of AI “up-
stream” of the enzyme blockade.
Much has been written about which precise enzyme
causes tissue AI/AII conversion. In humans in vivo, Schale-
kamp found that AI/AII conversion across organs was more
than 90% ACE inhibitable (19). On the other hand, in ex
vivo experiments, a role for chymase has been clearly
demonstrated, particularly in the extravascular interstitium
(9,20). Our studies did not attempt (nor were they de-
signed) to directly address the question of which enzyme
was most responsible, and therefore our results are not
definitive in this regard. Our data are, however, consistent
with previous data that ACE is solely responsible for
AI/AII conversion in the intravascular space (21). However,
our data do not exclude an additional contribution from
chymase, as we did not perform studies with specific
chymase inhibitor drugs. Our study was designed to answer
the clinically relevant question of whether, as CHF
progresses over time, vascular AI/AII conversion outstrips
the ability of ACE inhibitors to prevent it. Clearly that is
not the case. Therefore, even if chymase does contribute to
some extent to overall vascular AI/AII conversion, ACE
also contributes substantially, which means that increasing
the ACE inhibitor dose would further suppress vascular
AI/AII conversion in the clinical setting. Our study, how-
ever, does not assess whether adding an angiotensin receptor
antagonist would achieve a better overall effect than increas-
ing the dose of the ACE inhibitor. Our study merely
suggests that a higher ACE inhibitor dose is one option, as
suggested before (8).
The dose of lisinopril used here was the commonest dose
used in the UK as well as being in the middle of the two
doses used in the Assessment of Treatment with Lisinopril
and Survival (ATLAS) trial and being above the dose of
lisinopril used in the GISSI-3 study. Furthermore, the dose
of lisinopril used here matches the average bioequivalent
dose of enalapril used in the CONSENSUS I, SOLVD and
RALES trials. We were keen to match perceived normal
clinical practice, which explains our choice of drug and
dosage studied.
In pharmacologic studies, clinically used ACE inhibitors
vary in binding affinity for tissue-bound ACE (22–24). In
terms of tissue binding, lisinopril is considered intermediate
between the lipophilic highly tissue-bound ACE inhibitors
such as quinapril and ramipril and the poorly tissue-bound
ACE inhibitors such as captopril. However, because we
were studying patients with CHF, we wanted to use the
type of ACE inhibitors used in most of the major CHF
trials. Clearly, it would be intriguing to repeat these studies
with other ACE inhibitors that are more highly tissue
bound, to see if vascular AI/AII conversion escapes as much
with those agents as we found here with lisinopril.
An obvious question is the nature of the mechanism of
the reactivated vascular AI/AII conversion we found during
chronic ACE inhibitor therapy in CHF. Two main possi-
bilities exist. First, Fyhrquist et al. (25) found in tissue
culture that captopril induces ACE activity in human
endothelial cells (25). This is akin to the phenomenon of
upregulation of receptors when they are exposed constantly
to an antagonist drug. It is quite possible that constant
exposure to an ACE inhibitor causes induction of endothe-
lial ACE activity as a homeostatic mechanism. The second
possibility is that it is the progressive atherosclerotic process
itself that is inducing ACE activity (26–28). Further work
would be required to clarify these mechanisms more pre-
cisely.
Clinical implications. What are the potential clinical con-
sequences of these observations? The ATLAS trial found
that high dose lisinopril was more beneficial overall than low
dose lisinopril (29). High dose ACE inhibition produced a
nonsignificant 8% (p  0.128) reduction in mortality but a
significant 24% reduction in hospitalizations for heart fail-
ure (p  0.002). Intriguingly, recent data on the addition of
an AII receptor antagonist to an ACE inhibitor has simi-
larly produced a large effect on morbidity with little or no
effect on mortality (30). For example, in the recent unpub-
lished ValHeFT trial, valsartan dramatically reduced hospi-
talizations without altering total mortality. A picture is
therefore developing that AII reactivation during chronic
ACE inhibitor therapy mainly has an adverse effect on
morbidity rather than on mortality. The results we found
here raise the possibility that ACE inhibitor doses should be
gradually increased during chronic therapy.
In conclusion, vascular AI/AII conversion reactivates
despite conventional doses of chronic lisinopril therapy in
patients with CHF. This occurs over time even if the CHF
disease process is clinically apparently stable, but it also
occurs as the disease process progresses. However, this
reactivation of AI/AII conversion is not purely due to
non-ACE pathways. The reactivation is still ACE inhibitor
suppressible because increasing the dose of the ACE inhib-
itor suppresses vascular tissue AI/AII conversion markedly
even after the conversion has reactivated. Finally, there
would appear to be a total dissociation between reactivation
of the plasma RAS and vascular AI/AII conversion.
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